TOP 20 HAIR RESEARCH STUDIES OF THE YEAR
2020-2024
Each year in December, Dr Donovan announces choices for the top 20 hair research studies of the past year. A public webinar accompanies the announcement in celebration of studies that have a major impact on the diagnosis and treatment of hair loss.
TOP 20 HAIR RESEARCH STUDIES OF 2024
LINK TO THE FULL WEBINAR RECORDING
GROUP 1 STUDIES: MINOXIDIL
Penha MA et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol . 2024 Apr 10:e240284. doi: 10.1001/jamadermatol.2024.0284. Online ahead of print
Salas J et al. Characterizing low-dose oral minoxidil-induced peripheral edema in alopecia patients. J Am Acad Dermatol . 2024 Nov 16:S0190-9622(24)03211-0. doi: 10.1016/j.jaad.2024.09.078. Online ahead of print
Jimenez-Cauhe J et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2024 Jan;115(1):28-35.
GROUP 2 STUDIES: FINASTERIDE
O M Moreno-Arrones et al. Impact of Finasteride and Dutasteride in Beard Thickness in Men With Androgenetic Alopecia: A 453-patient Retrospective Trial. Actas Dermosifiliogr . 2024 Nov-Dec;115(10):1015-1016. doi: 10.1016/j.ad.2023.05.046. Epub 2024 Jul 20.
Chen L-C et al. 5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study. J Am Acad Dermatol . 2024 Oct 21:
Rohan TZ, Grace Turchetta, Sherry Yang. Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors. Arch Dermatol Res . 2024 Nov 26;317(1):46. doi: 10.1007/s00403-024-03542-8.
GROUP 3 STUDIES: TELOGEN EFFLUVIUM
Godfrey H et al. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol . 2024 Jun 24. doi: 10.1111/jdv.20197. Online ahead of print.
Hirose A et al. Postpartum hair loss is associated with anxiety. J Obstet Gynaecol Res . 2024 Dec;50(12):2239-2245. doi: 10.1111/jog.16130. Epub 2024 Oct 27
GROUP 4 STUDIES: ALOPECIA AREATA
David E et al. . Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study. Arch Dermatol Res . 2024 Jul 23;316(7):487. doi: 10.1007/s00403-024-03225-4.
Piliang M et al. Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata. Br J Dermatol . 2024 Oct 21:
Nohria A et al. Alopecia areata and cardiovascular comorbidities: A cross-sectional analysis of the All of Us research program. JAAD Int. 2024 Apr 8:16:46-48. doi: 10.1016/j.jdin.2024.03.024. eCollection 2024 Sep.
Caldas S et al. Association of alopecia areata and ischemic heart disease and cerebrovascular in U.S. adults: an all of us database study. Arch Dermatol Res . 2024 May 22;316(5):202. doi: 10.1007/s00403-024-02959-5.
GROUP 5 STUDIES: FRONTAL FIBROSING ALOPECIA
Pindado-Ortega C et al. Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series. Actas Dermosifiliogr . 2024 Nov 12:
Chen L-C et al. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia. J Am Acad Dermatol. 2024 Jun;90(6):1260-1262. doi: 10.1016/j.jaad.2024.01.060. Epub 2024 Feb 2.
Williams KN et al. Topical ruxolitinib in the management of frontal fibrosing alopecia and/or lichen planopilaris: A single-center retrospective cohort study. J Am Acad Dermatol. 2025 Jan;92(1):170-172. doi: 10.1016/j.jaad.2024.09.032. Epub 2024 Sep 26.PMID: 39341357 No abstract available.
GROUP 6 STUDIES: CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA
Obi A et al. Doxycycline for central centrifugal cicatricial alopecia: A single center retrospective analysis. J Am Acad Dermatol . 2024 Aug;91(2):331-333.
Bao A et al. Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia. JAMA Dermatol . 2024 Sep 4:e243062. doi: 10.1001/jamadermatol.2024.3062. Online ahead of print.
GROUP 7 STUDIES: FOLLICULITIS DECALVANS
Doche I, Sotto MN, Hordinsky MK, Melhado IP, Gerlero P, Rivitti-Machado MC.Clin Exp Dermatol. 2024 Sep 28:llae394. doi: 10.1093/ced/llae394. Hydroxychloroquine may be beneficial as an adjuvant therapy for folliculitis decalvans: a 5-year retrospective study with 49 patients.
GROUP 8 STUDIES: SCARRING ALOPECIA (GENERAL)
Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2024
GROUP 9 STUDIES: LICHEN PLANOPILARIS
Kai-Wen Chuang et al. Association of lichen planopilaris with cardiovascular and metabolic disorders: A systematic review and meta-analysis. Clin Exp Dermatol . 2024 Oct 18:llae446. doi: 10.1093/ced/llae446. Online ahead of print.
TOP 20 HAIR RESEARCH STUDIES OF 2023
DERMATOPATHOLOGY
Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.
ANDROGENETIC ALOPECIA
Gupta AK et al. The relative efficacy of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. J Cosmet Dermatol. 2023 Jun 29
Jimenez-Cauhe J et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
ALOPECIA AREATA
Gandhi et al. The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata. Dermatol Ther (Heidelb). 2023 Jan;13(1):285-298.
Li SJ et al. Experiencing Workplace Bullying in Patients with Alopecia Areata: A Cross-Sectional Survey Study. Skin Appendage Disord. 2023 Aug;9(4):258-261
Kazmi A et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.
King B et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023 May 6;401(10387):1518-1529.
George P et al. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023
TELOGEN EFFLUVIUM
Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.
TINEA CAPITIS
Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.
COSMETIC DERMATOLOGY
Landau M et al. Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37:30-34
GENERAL SCARRING ALOPECIA
Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2023 Nov 19:S
LICHEN PLANOPILARIS
Lim SH et al. Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235
FOLLICULITIS DECALVANS
Matard B et al. Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association. Br J Dermatol 2022 Dec;187(6):1026-1028.
DISCOID LUPUS
Fredeau L et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol. 2023 Mar;88(3):551-559.
DISSECTING CELLULITIS
Cajas-Garcia MS et al. Distinct presentations of scalp dissecting cellulitis manifesting with furrows and gyri. J Eur Acad Dermatol Venereol. 2023 Feb 3.
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA
Joshi TP et al. Comorbidities in patients with central centrifugal cicatricial alopecia: a case-control study. Int J Dermatol. 2023 Nov 23.
ACNE KELOIDALIS NUCHAE
Lobato-Berezo A et al. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1.
TOP 20 HAIR RESEARCH STUDIES OF 2022
STUDIES IN FEMALE PATTERN HAIR LOSS AND MALE PATTERN HAIR LOSS
Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
STUDIES IN ALOPECIA AREATA
King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
STUDIES IN SCARRING ALOPECIA
Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
STUDIES IN VARIOUS TOPICS
Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
TOP 20 HAIR RESEARCH STUDIES OF 2021
Group 1: Androgenetic Alopecia
Jiang Y et al. Relationship between the exercise and severity of androgenic alopecia. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Jul 28;46(7):725-730.
DuBois J et al. Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial. Clin Cosmet Investig Dermatol. 2021 Oct 15;14:1507-1517.
Panchaprateep et al. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther. 2020 Dec;10(6):1345-1357
Kang MJ et al. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study. J Am Acad Dermatol. 2021 Jan;84(1):172-173.
Zaky M et al. Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study. J Cosmet Dermatol 2021 Apr;20(4):1154-1159.
Mostafa D et al. Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. J Pharm Pharm Sci 2021;24:191-199.
Abdel-Raouf et al. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. Dermatol Ther. 2021 Jan;34(1):e14678.
Piraccini et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2021 Oct 11.
Group 2: Alopecia Areata
Glickman JW et al. Cross sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021; 84(2): 370-80.
Kim K-H. Characterization of a cohort of 294 patients with late-onset alopecia areata. J Am Acad Dermatol. 2021 Nov;85(5):1336-1337.
Group 3: Scarring Alopecia
Scarring Alopecia - CCCA
Samrao A. Evaluating the association of central centrifugal cicatricial alopecia (CCCA) and fibroproliferative disorder. Dermatol Online J 2021; Aug 15; 27(8).
Brown-Korsah et al. Association of breast and colorectal cancer in patients with central centrifugal cicatricial alopecia: A retrospective, cross-sectional pilot study. J Am Acad Dermatol 2021 Mar;84(3):859-860.
Scarring Alopecia - Frontal Fibrosing Alopecia
Grassi S et al. Frontal fibrosing alopecia and genital Lichen sclerosus: Single-center experience. J Cosmet Dermatol; 2021; Feb; 20(2): 615-620
Scarring Alopecia - Lichen Planopilaris
Conic et al. Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.
Vano-Galvan S et al. Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol 2021 Jun;84(6):1684-1686.
Group 4: Minoxidil Toxicity in Pets
Tater KC et al.Topical Minoxidil Exposures and Toxicoses in Dogs and Cats: 211 Cases (2001-2019). J Am Animal Hosp Assoc 2021; 57(5): 225-231
Group 5: Breast Implant Illness and Hair Loss
Magno-Padron D. A population-based study of breast implant illness. Arch Plast Surg. 2021 Jul;48(4):353-360.
Group 6: Clinical Evaluation
Pathoulas JT. Evaluation of standardized scalp photography on patient perception of hair loss severity, anxiety, and treatment. J Am Acad Dermatol 2021 Dec;85(6):1640-1641.
Group 7: Hair Loss and Chemotherapy
Bhoyrul B et al. Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors. JAMA Dermatol. 2021 Nov 1;157(11):1335-1342.
Dilawari et al. Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? Oncologist. 2021 Apr;26(4):292-e548.
TOP 20 HAIR RESEARCH STUDIES OF 2020
STUDY 1
Chretien et al. Direct acting oral anticoagulants and alopecia: to go further with data mining in pharmacovigilance databases. Eur J Clin Pharmacol 2020 Aug 76(8):1197-1198
Key message: Direct acting oral anticoagulants include drugs like dabigatran rivaroxaban, apixaban, edoxaban, and betrixaban. Direct acting anticoagulants carry a slightly increased risk of hair loss. Fortunately, most users will not experience hair loss
Link to description in video Chretien et al, 2020.
STUDY 2
Moreno-Arrones et al. SARS-CoV-2 induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol 2020 Nov
Key message: Hair shedding occurs in some patients experiencing COVID19 infection. Shedding occurs on average 58 days after diagnosis. Up to 13 % of the 214 patients in the study were asymptomatic meaning that they were completely surprised their shedding ultimately ended up being due to COVID 19. We need to consider COVID 19 infection in all patients who experience hair shedding.
Link to description in video Moreno-Arrones et al, 2020.
STUDY 3
Goren et al. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain – a potential clue to the role of androgens in COVID-19 severity. April 2020
Key message: This was one of the first studies in the dermatological literature to draw attention to the relationship between male balding and thee risk of more severe COVID 19 infections. This study set the stage for further studies.
Link to description in video: Goren et al, 2020.
STUDY 4
Ying-Xiu D et al. Bidirectional association between alopecia areata and major depressive disorder among probands and unaffected siblings: A nationwide population-based study. J Am Acad Dermatol May 2020
Key message: This study illustrated the complex relationship between alopecia areata and depression and highlighted the complexity of the genetic links between these issues. Patients with alopecia areata were more likely than controls to experience depression – but so were their siblings. Patients with depression were more likely than controls to experience alopecia areata – but so were their siblings.
Link to description in video: Ying-Xiu D et al, 2020
STUDY 5
Lee et al. Epidemiology of alopecia areata, ophiasis, totalis and universalis: A systematic review and meta-analysis. J Am Acad Dermatol March 2020
Key message: This study evaluated the changing epidemiology of alopecia areata. The authors suggested that the prevalence of alopecia areata may be increasing over time.
Link to description in video: Lee et al, 2020
STUDY 6: Yee et al. Efficacy of different concentrations of intralesional triamcinolone acetonide for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol April 2020
Key message: This study showed that low concentrations (below 5 mg per mL) of triamcinolone acetonide can be helpful in alopecia areata although 5 mg per mL concentrations are probably the most consistently effective. The risk of atrophy was estimated to be 20 % with 10 mg/mL and only 3 % with 5 mg/mL concentrations.
Link to description in video: Yee et al, 2020
STUDY 7
Conic RR. Prevalence of cardiac and metabolic diseases among patients with alopecia areata. J Eur Acad Dermatol Venereol. Aug 2020
Key message: This very large study highlighted the increased risk of cardiac disease and metabolic dysfunction in patients with alopecia areata. In regression models, patients with AA had significantly increased odds for hypertension, hyperlipidemia, obesity, diabetes mellitus, metabolic syndrome, coronary artery disease, atrial fibrillation and stroke.
Link to description in video: Conic et al, 2020
STUDY 8: Waskiel-Burnat et al. Alopecia areata predictive score: A new Trichoscopy-based tool to predict treatment outcome in patients with patchy alopecia areata. J Cosmet Dermatol. Mar 2020
Key message: In patients with patchy alopecia areata, 6 trichoscopic features 2 months after starting treatment can help predict whether or not patients will ultimately regrow hair.
Link to description in video: Waskiel-Burnat et al, 2020
STUDY 9
Ramos PM et al. Minoxidil 1 mg versus minoxidil 5 % topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol Jan 2020
Key message: In a small study comparing 5 % minoxidil solution to 1 mg orally, results were found to be similar. 5 % minoxidil solution caused more irritation although 1 mg caused more hair growth on the face and body.
Link to description in video: Ramos et al, 2020
STUDY 10
Sanabria et al. Adverse Effects of Low-dose Oral Minoxidil for Androgenetic Alopecia in 435 patients. J Am Acad Dermatol Nov 2020
Key message: Oral minoxidil comes with certain side effects that all physicians and users must know about. These increase excessive hair growth on the body, hair shedding, swelling in the feet and face, headaches, dizziness, insomnia and heart palpitations.
Link to description in video: Sanabria et al, 2020
STUDY 11 and STUDY 12
Ismail et al. Safety of Oral Bicalutamide in female pattern hair loss: A retrospective review of 316 patients. J Am Acad Dermatol. Nov 2020
Fernandez-Nieto et al. Bicalutamide: A potential pure anti-androgens with Potential Benefit in Treating Female Androgenetic Alopecia. J Am Acad Dermatol. Nov 2020
Key message: The pure antiandrogen bicalutamide may be an option for some patients with female androgenetic alopecia. Ismail et al was a study of 316 patients receiving bicalutamide and Fernandez Nieto was a study of 44 patients. Side effects need to be understood by all prescribers and users and include a low incidence of liver enzyme elevation. Other side effects include gastrointestintal upset, edema, shedding, headaches may also occur.
Link to description in video: Bicalutamide Studies
STUDY 13
Nguyen et al. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatology Nov 2020
Key message: A pharmacovigilance study suggested that young male users of finasteride 1 mg may be at increased risk of suicidal thoughts but not completed suicide.
Link to description in video: Nguyen et al, 2020
STUDY 14
Vano-Galvan S et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice. Dermatol Ther Jan 2020
Key message: Dutasteride 0.5 mg used 5 to 7 times weekly can be a useful treatment for male pattern balding. Side effects occur in 6.5 % of users and 2.6 % needed to stop the medication due to side effects such as decreased libido, gynecomastia, mood changes and erectile dysfunction. Low dose oral dutasteride (less than 3 times weekly) was not associated with side effects in this small study.
Link to description in video: Vano-Galvan et al, 2020
STUDY 15
Starace M et al. Atypical Presentation of Congenital Triangular Alopecia: A Case Series in Italy. Dermatol Pract Concept Oct 2020.
Key message: Congenital triangular alopecia could possibly affect other areas besides the temples.
Link to description in video: Starace et al, 2020
STUDY 16
Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020
Key message: Low dose naltrexone does not appear to add any benefit to patients with lichen planopilaris receiving treatment with topical clobetasol.
Link to description in video: Lajevardi et al, 2020
STUDY 17
Trager et al. Prevalence Estimates for Lichen Planopilaris and Frontal Fibrosing Alopecia in a New York City Health Care System J Am Acad Dermatol Oct 2020
Key message: The first study of its kind to attempt to systematically estimate the prevalence of LPP and FFA in a defined population. Overall, the prevalence of LPP was estimate to be 1 in 5882 and the prevalence of FFA was estimate to be 1 in 6666.
Link to description in video: Trager et al, 2020
STUDY 18
Pindado-Ortega C et al. Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia. J Am Acad Dermatol Oct 2020
Key message: Dutasteride appears to be more effective than standard treatments like doxycycline, hydroxychloroquine, isotretinoin and finasteride. Dutasteride 5 to 7 times weekly is more effective than 3 times weekly although lower doses can still be effective.
Link to description in video: Pindado-Ortega et al, 2020
STUDY 19: Prasad et al. Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: A cohort study. J Am Acad Dermatol Aug 2020
Key message: There may be an association between being diagnosed with lichen planopilaris and frontal fibrosing alopecia and having positive patch test reactions to various agents such as fragrance, linalool, gallates and MCI/MI. Patients found to have specific allergies and ultimately avoided these allergens in their daily life ultimately experienced reduced disease activity.
Link to description in video: Prasad et al, 2020
STUDY 20
Erinolaoluwa F et al. Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports Feb 2020
Key message: Topical 10 % metformin may have benefit in the treatment of central centrifugal cicatricial alopecia.
Link to description in video: Erinolaoluwa et al, 2020